MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Innoviva Inc

Geschlossen

BrancheGesundheitswesen

17.34 0.87

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

16.95

Max

17.41

Schlüsselkennzahlen

By Trading Economics

Einkommen

110M

64M

Verkäufe

12M

100M

KGV

Branchendurchschnitt

30.561

35.739

Gewinnspanne

63.508

Angestellte

127

EBITDA

111M

84M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+106.98% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-69M

1.1B

Vorheriger Eröffnungskurs

16.47

Vorheriger Schlusskurs

17.34

Nachrichtenstimmung

By Acuity

46%

54%

179 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Innoviva Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Okt. 2025, 16:58 UTC

Ergebnisse

BMW Trims 2025 View, Citing Weaker Performance in China

7. Okt. 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. Okt. 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. Okt. 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. Okt. 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 20:44 UTC

Heiße Aktien

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. Okt. 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. Okt. 2025, 19:23 UTC

Akquisitionen, Fusionen, Übernahmen

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. Okt. 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. Okt. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. Okt. 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. Okt. 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. Okt. 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. Okt. 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. Okt. 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. Okt. 2025, 14:52 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Innoviva Inc Prognose

Kursziel

By TipRanks

106.98% Vorteil

12-Monats-Prognose

Durchschnitt 35.6 USD  106.98%

Hoch 55 USD

Tief 17 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Innoviva Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

4

Buy

0

Halten

1

Sell

Technischer Score

By Trading Central

18.57 / 18.75Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

179 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat